145 related articles for article (PubMed ID: 22669332)
21. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density.
Byrne C; Colditz GA; Willett WC; Speizer FE; Pollak M; Hankinson SE
Cancer Res; 2000 Jul; 60(14):3744-8. PubMed ID: 10919644
[TBL] [Abstract][Full Text] [Related]
22. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
26. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
[TBL] [Abstract][Full Text] [Related]
27. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Burns T; Maciejewski SR; Hamilton WR; Zheng M; Mooss AN; Hilleman DE
Pharmacotherapy; 2007 May; 27(5):633-8. PubMed ID: 17461697
[TBL] [Abstract][Full Text] [Related]
28. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
29. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
30. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial.
Wenger NK; Barrett-Connor E; Collins P; Grady D; Kornitzer M; Mosca L; Sashegyi A; Baygani SK; Anderson PW; Moscarelli E
Am J Cardiol; 2002 Dec; 90(11):1204-10. PubMed ID: 12450599
[TBL] [Abstract][Full Text] [Related]
31. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
[TBL] [Abstract][Full Text] [Related]
32. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
Hobbs T; Caso R; McMahon D; Nymark M
Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
[TBL] [Abstract][Full Text] [Related]
33. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
[TBL] [Abstract][Full Text] [Related]
34. Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3.
Duschek EJ; Gooren LJ; Netelenbos C
Maturitas; 2005 Jul; 51(3):286-93. PubMed ID: 15978972
[TBL] [Abstract][Full Text] [Related]
35. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[TBL] [Abstract][Full Text] [Related]
36. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women.
Probst-Hensch NM; Wang H; Goh VH; Seow A; Lee HP; Yu MC
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):739-46. PubMed ID: 12917205
[TBL] [Abstract][Full Text] [Related]
37. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
38. Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.
Schairer C; Hill D; Sturgeon SR; Fears T; Pollak M; Mies C; Ziegler RG; Hoover RN; Sherman ME
Int J Cancer; 2004 Feb; 108(5):773-9. PubMed ID: 14696106
[TBL] [Abstract][Full Text] [Related]
39. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
Fryar-Tita EB; Das JR; Davis JH; Desoto JA; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(3B):1393-9. PubMed ID: 17595753
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density.
Diorio C; Pollak M; Byrne C; Mâsse B; Hébert-Croteau N; Yaffe M; Coté G; Bérubé S; Morin C; Brisson J
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1065-73. PubMed ID: 15894654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
